Description
An ADAM and MMP inhibitor; inhibits ADAM17/TACE (IC50 = 8.4 nM in a cell-free enzyme assay); inhibits MMP-1, -2, -7, -9, -13, and -14, as well as ADAM-TS-4 in vitro (IC50s = 6.6, 4.7, 26, 12, 3, 26, and 100 nM, respectively); inhibits ADAM8, -10, -12, and -17/TACE (Kis = 21, 16, 1.8, and 0.079 nM, respectively, in cell-free enzyme assays); inhibits LPS-induced TNF-α secretion in Raw and THP-1 cells (IC50s = 40 and 200 nM, respectively), as well as in isolated human monocytes and whole blood (IC50s = 190 and 300 nM, respectively); inhibits the production of TNF-α ex vivo in synovium isolated from the inflamed joints of patients with rheumatoid arthritis (IC50s = 50 = 5 mg/kg) and reduces disease severity in mouse models of collagen-induced arthritis; decreases cell viability of (ED50s = 1.3-8.1 µM) and induces tumor apoptosis and reduces tumor growth in an MMTV-ErbB2/neu mouse model of breast cancer at 100 mg/kg
Formal name: (3S)-4-[[4-(2-butyn-1-yloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-3-thiomorpholinecarboxamide
Synonyms:
Molecular weight: 398.5
CAS: 287403-39-8
Purity: ≥98%
Formulation: A solid